Journal
NATURE REVIEWS CANCER
Volume 13, Issue 8, Pages 559-571Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nrc3563
Keywords
-
Categories
Funding
- US National Cancer Institute (NCI)
- NCI [R01CA155160, R01CA070940]
- US Department of Defense Breast Cancer Research Program Fellowship [W81XWH-10-1-0345]
- Pharmaceutical Research and Manufacturers of America
- ACS Spin-Odyssey Postdoctoral grant [11984-7-PF-10-228-01-CSM]
Ask authors/readers for more resources
The Abelson (ABL) family of nonreceptor tyrosine kinases, ABL1 and ABL2, transduces diverse extracellular signals to protein networks that control proliferation, survival, migration and invasion. ABL1 was first identified as an oncogene required for the development of leukaemias initiated by retroviruses or chromosome translocations. The demonstration that small-molecule ABL kinase inhibitors could effectively treat chronic myeloid leukaemia opened the door to the era of targeted cancer therapies. Recent reports have uncovered roles for ABL kinases in solid tumours. Enhanced ABL expression and activation in some solid tumours, together with altered cell polarity, invasion or growth induced by activated ABL kinases, suggest that drugs targeting these kinases may be useful for treating selected solid tumours.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available